Company profile

Biocon Biologics

Privately held: no public share price · India

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Jobevne (bevacizumab-nwgd)
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung Cancer
Bmab1700
Phase 1
Insulin receptor (basal)Peptide
Indication not yet linked

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.